Strong market adoption of Syn-One Test™ to help clinicians diagnose Parkinson’s Disease and other neurological disorders
Enrique Carrazana, MD Brings Deep Expertise in Neuroscience and the Life Sciences Industry to Support the Company’s Mission
Strategic Collaboration Educates Neurology Community About Syn-One Test™
Innovators of the Syn-One Test™ Building Market Presence and Infrastructure
Poised for Growth After Successfully Launching First Skin-Based Test for Parkinson’s
Grant Supports the Continued Validation and Enhancement of the Syn-One Test™ To Help Physicians Diagnose Parkinson’s Disease and Other Serious Disorders
CND will use its novel cutaneous neurodiagnostics platform to detect and measure changes in TDP-43 in patients treated with edaravone
Company launches the Syn-One Test™ as the first commercially available skin-based test to help physicians confirm diagnosis of Parkinson’s disease and other neurodegenerative disorders